IPF fibroblasts were treated with two highly potent and selective inhibitors of PI3K pathway, LY294002 and wortmannin (Fig 7A) or increasing concentrations of AG1879 (PP2), a FAK inhibitor (Fig 7B) followed by TGFβ. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.